We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pulmotect reported positive topline results from their randomized, placebo-controlled Phase-2 trial of PUL-042 against COVID-19. Patients treated with inhaled PUL-042 had a statistically significant reduction...
A recent study in preschoolers with cystic fibrosis (CF) conducted by Cystic Fibrosis Foundation Therapeutics used PARI's LC Sprint Jr. nebulizer, Vios PRO compressor.....